Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Yuzo Kodama

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1223-7147; OpenAlex author ID A5059499039. Sources: OpenAlex.

Their work

Papers
34 (first author 2, last author 12)
Trials
0
Grants
0
Labs led
1
Collaborators
114
Papers, trials and grants by year

2014: 3 papers · 2015: 1 paper · 2016: 2 papers · 2017: 3 papers · 2018: 1 paper · 2019: 2 papers · 2020: 3 papers · 2021: 2 papers · 2022: 3 papers · 2023: 6 papers · 2024: 7 papers · 2025: 1 paper

Papers 34

  1. Multicenter Comparative Study of 6- and 10-mm Fully Covered Self-Expandable Metal Stents for Malignant Distal Biliary Obstruction During Neoadjuvant Chemothera… Last author DOI 10.1002/jhbp.12157↗
  2. Temporal progression of pancreatic cancer computed tomography findings until diagnosis: A large-scale multicenter study. Last author DOI 10.1002/ueg2.12557↗
  3. Impact of intratumoral microbiome on tumor immunity and prognosis in human pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00535-023-02069-5↗
  4. Association of pancreatic atrophy patterns with intraductal extension of early pancreatic ductal adenocarcinoma: a multicenter retrospective study. Last author DOI 10.1007/s00535-024-02149-0↗
  5. Near-infrared photoimmunotherapy as a complementary modality to in situ vaccine in a preclinical pancreatic cancer model. Co-author DOI 10.1016/j.bbrc.2024.150534↗
  6. Wnt-deficient and hypoxic environment orchestrates squamous reprogramming of human pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41556-024-01498-5↗
  7. Role of Wnt5b-Ror1 signaling in the proliferation of pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1111/gtc.13115↗
  8. Treatment and Prognosis for Pancreatic Duct Disruption Associated With Pancreatic Cancer: A Case Series of 15 Patients. Last author DOI 10.7759/cureus.67482↗
  9. Integrated analysis of tertiary lymphoid structures in relation to tumor-infiltrating lymphocytes and patient survival in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00535-022-01939-8↗
  10. A comprehensive analysis of tumor-stromal collagen in relation to pathological, molecular, and immune characteristics and patient survival in pancreatic ductal… Last author DOI 10.1007/s00535-023-02020-8↗
  11. A case of pancreatic ductal adenocarcinoma concomitant with IgG4-related disease in the pancreas and the stomach. Last author DOI 10.1007/s12328-023-01814-w↗
  12. Benefits of pancreatic parenchymal endoscopic ultrasonography in predicting microscopic precancerous lesions of pancreatic cancer. Last author DOI 10.1038/s41598-023-38920-1↗
  13. Blockage of retinoic acid signaling via RARγ suppressed the proliferation of pancreatic cancer cells by arresting the cell cycle progression of the G1-S phase. Co-author DOI 10.1186/s12935-023-02928-4↗
  14. Association of Sarcopenia with a Poor Prognosis and Decreased Tumor-Infiltrating CD8-Positive T Cells in Pancreatic Ductal Adenocarcinoma: A Retrospective Anal… Last author DOI 10.1245/s10434-023-13569-2↗
  15. Comprehensive Analysis of Molecular Biologic Characteristics of Pancreatic Ductal Adenocarcinoma Concomitant with Intraductal Papillary Mucinous Neoplasm. Last author DOI 10.1245/s10434-022-11704-z↗
  16. Increased expression of SPRR1A is associated with a poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0266620↗
  17. ARF6-AMAP1 pathway induces pancreatic cancer cells to express immunosuppressive chemokines Co-author DOI 10.21203/rs.3.rs-1897319/v1↗
  18. Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial). Co-author DOI 10.1007/s00280-020-04174-1↗
  19. Correction: CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1158/0008-5472.can-21-1255↗
  20. CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1158/0008-5472.can-19-2745↗
  21. Possibility of detecting intraductal papillary mucinous neoplasms using metabolite biomarkers for pancreatic cancer. Co-author DOI 10.2217/bmm-2019-0587↗
  22. Prospective Study Using Plasma Apolipoprotein A2-Isoforms to Screen for High-Risk Status of Pancreatic Cancer. Co-author DOI 10.3390/cancers12092625↗
  23. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nat… Co-author DOI 10.1016/j.surg.2019.06.023↗
  24. ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer. Co-author DOI 10.1073/pnas.1901765116↗
  25. Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer. Co-author DOI 10.1186/s13014-018-1063-5↗
  26. Utility of KRAS mutational analysis in the preoperative diagnosis of synchronous pancreatic cancer and intrahepatic cholangiocarcinoma: A case report. Co-author DOI 10.1097/md.0000000000009217↗
  27. A Prospective Study of Intensity-modified Radiation Therapy in Comparison with Conventional 3D-RT for BR Pancreatic Cancer Patients with Arterial Involvement. Co-author DOI 10.21873/anticanres.12172↗
  28. Familial pancreatic cancer: Concept, management and issues. Co-author DOI 10.3748/wjg.v23.i6.935↗
  29. Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy. Co-author DOI 10.1007/s10147-015-0864-x↗
  30. Clinicopathological Characteristics of Young Patients With Pancreatic Cancer: An Analysis of Data From Pancreatic Cancer Registry of Japan Pancreas Society. Co-author DOI 10.1097/mpa.0000000000000636↗
  31. Acute Pancreatitis as a Possible Indicator of Pancreatic Cancer: The Importance of Mass Detection. Last author DOI 10.2169/internalmedicine.54.4068↗
  32. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Co-author DOI 10.1002/cam4.204↗
  33. Comparative outcomes between initially unresectable and recurrent cases of advanced pancreatic cancer following palliative chemotherapy. Co-author DOI 10.1097/mpa.0000000000000050↗
  34. Perfusion in the tissue surrounding pancreatic cancer and the patient's prognosis. Co-author DOI 10.1155/2014/648021↗

Closest collaborators

The 25 strongest of 114 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Atsuhiro Masuda · 14 shared papers, 2020–2025 · strength 2.13
  2. Arata Sakai · 12 shared papers, 2020–2025 · strength 1.76
  3. Hirochika Toyama · 12 shared papers, 2021–2024 · strength 1.69
  4. Takashi Kobayashi · 12 shared papers, 2020–2024 · strength 1.64
  5. Kohei Yamakawa · 9 shared papers, 2022–2024 · strength 1.30
  6. Takumi Fukumoto · 9 shared papers, 2022–2024 · strength 1.27
  7. Masanori Gonda · 9 shared papers, 2022–2024 · strength 1.26
  8. Masahiro Tsujimae · 8 shared papers, 2022–2024 · strength 1.09
  9. Shohei Abe · 7 shared papers, 2022–2024 · strength 0.94
  10. Takeshi Tanaka · 7 shared papers, 2022–2024 · strength 0.93
  11. Keitaro Sofue · 7 shared papers, 2022–2024 · strength 0.93
  12. Ryota Nakano · 6 shared papers, 2020–2025 · strength 0.93
  13. Tomoo Itoh · 7 shared papers, 2022–2024 · strength 0.93
  14. Mika Miki · 6 shared papers, 2023–2024 · strength 0.86
  15. Shigeto Masuda · 6 shared papers, 2022–2024 · strength 0.76
  16. Yoshiyuki Harada · 5 shared papers, 2023–2024 · strength 0.70
  17. Hiroshi Seno · 5 shared papers, 2017–2024 · strength 0.63
  18. Shigeto Ashina · 5 shared papers, 2022–2023 · strength 0.62
  19. Mamoru Takenaka · 3 shared papers, 2023–2025 · strength 0.54
  20. Takuya Ikegawa · 4 shared papers, 2020–2024 · strength 0.52
  21. Yoshihiro Nishikawa · 5 shared papers, 2014–2022 · strength 0.45
  22. Takashi Aoi · 2 shared papers, 2022–2023 · strength 0.36
  23. Tsutomu Chiba · 6 shared papers, 2014–2021 · strength 0.36
  24. Akihito Machinaga · 2 shared papers, 2023–2024 · strength 0.36
  25. Yuki Oka · 2 shared papers, 2024 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.